Can medical cannabis help with cachexia?
Appetite is the effect cannabis is best known for, which makes cachexia the condition where expectation and evidence diverge most sharply. The distinction between losing your appetite and losing muscle is the whole of it.
The short answer
- Cachexia is not the same as appetite loss. It is a wasting syndrome driven by the underlying illness, involving muscle loss.
- The largest randomised trial was negative. A cannabis extract did not beat placebo on appetite or quality of life in cancer cachexia.
- Eating more does not reverse it. That is what separates cachexia from starvation.
- Nausea is a different question, and one with better evidence behind it.
- Treating the underlying illness comes first, alongside specialist dietetic and palliative care input.
What cachexia actually is
A metabolic syndrome that comes with a serious underlying illness — most often advanced cancer, but also heart failure, COPD, kidney disease and HIV. It involves loss of skeletal muscle, with or without loss of fat, and it cannot be fully reversed by eating more.
That last point is what makes cachexia different from simple undernutrition, and it is why a medicine that increases appetite does not automatically help. The inflammatory and metabolic processes driving the muscle loss continue regardless of how much someone manages to eat.
It matters clinically because the two are often treated as the same problem. Poor appetite from nausea, taste changes or treatment side effects is a real and separate difficulty, and one where there is more to offer.
What the evidence shows
The definitive trial in this area was negative. A multicentre phase III study compared a cannabis extract, THC alone and placebo in patients with cancer-related anorexia-cachexia syndrome, and found no significant difference in appetite or quality of life.
The trial behind that paragraph
Strasser F, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology, 2006. The trial was stopped early for insufficient differences between study arms.
That is an unusually clear result for this field, and it deserves to be stated plainly rather than buried. Later reviews have not overturned it. Where cannabinoids do have an established role in cancer care it is for chemotherapy-induced nausea and vomiting, which is a different indication with a different evidence base.
None of that means appetite never improves in individual patients. It means the controlled evidence does not support cachexia itself as a reason to prescribe. It is also worth being clear about why a negative trial is not simply an absence of good news: a large, well-designed study that looked for a benefit and did not find one is stronger evidence than a collection of individual reports of people who felt better, because it accounts for the natural course of the illness and for the improvement people often describe after starting any treatment. Taking that result seriously is part of giving you honest information rather than comfortable information.
What a specialist will look at instead
Whether the problem is genuinely cachexia, or a treatable symptom sitting on top of it. The second is far more actionable than the first.
- Nausea and vomiting, including from chemotherapy, where there are established treatments
- Pain, which suppresses appetite and is treatable in its own right
- Mouth problems, taste changes, constipation and early satiety
- Low mood, which is common and under-treated in advanced illness
- Whether specialist dietetic and palliative care input is already in place
Several of those overlap with questions covered in medical cannabis for nausea and appetite loss and cancer-related pain.
The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?
Risks worth weighing here in particular
People with cachexia are frequently frail, often elderly, and usually taking several other medicines. That combination raises the significance of side effects that would be minor in someone else.
Dizziness and sedation matter more when falls are already a risk. Drug interactions matter more when the medicines list is long. And the time and cost of pursuing a treatment with negative trial evidence is itself a cost, in a situation where time is often what there is least of.
That is not an argument for doing nothing. It is an argument for making sure the treatable symptoms have genuinely been addressed first.
Why the appetite effect does not translate here
Increasing appetite is the effect cannabis is best known for, and there is a real biological basis for it: the body has an endocannabinoid system — receptors and signalling molecules found throughout the brain and gut — that is involved in appetite and metabolism. That is exactly why the expectation around cachexia is so strong, and why the trial result is so counterintuitive.
The reason the two come apart is that cachexia is not driven by appetite. The muscle loss is produced by inflammatory and metabolic changes set off by the underlying illness, and those continue regardless of how much someone eats or how hungry a medicine makes them feel. A drug that nudges appetite is acting on the wrong part of the problem. That is the difference between cachexia and simple undernutrition, and it is why a plausible mechanism for appetite is not a mechanism for treating the syndrome. For the underlying biology, see the endocannabinoid system explained and THC and CBD explained.
What treatment would involve if it is considered
Where a specialist does consider a cannabis-based medicine — usually for a specific treatable symptom sitting alongside the cachexia rather than for the wasting itself — the approach is the cautious one used across this field: start at a low dose, increase slowly, and review honestly.
The usual formats are oils or capsules taken by mouth and dried flower for vaporising, though inhaled routes are often unsuitable for someone who is very unwell. Your specialist chooses the format and dose with you, and there is no dose that fits everyone — how a dose is set and adjusted is covered in how a dose is decided and adjusted, and the formats in how cannabis-based medicines are taken.
Follow-up carries extra weight here. Because people with cachexia are frequently frail and on several medicines, side effects and interactions are watched closely, and treatment that is not clearly helping is stopped rather than continued out of hope. The common unwanted effects are set out in side effects of cannabis-based medicines, and how soon any effect might appear in how long cannabis medicines take to work.
Questions worth asking
If you are weighing this up for yourself or someone you care for, a few direct questions help keep the focus on what can actually be improved.
- Is the problem genuinely cachexia, or a treatable symptom — nausea, pain, low mood, mouth or taste problems — sitting on top of it?
- Have specialist dietetic and palliative care input already been arranged?
- What is the realistic goal here, given that the largest trial in cancer cachexia was negative?
- How would any medicine interact with the others, and who will monitor for side effects?
- How and when would we decide it is not working and stop?
If you want to take this further
The useful next step is a proper assessment, not a longer reading list. Gather your diagnosis, the treatments you have already tried and what happened with each, and a current list of your medicines — that is what a specialist needs in order to give you a straight answer.
The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If cachexia is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.
Frequently asked questions
Does medical cannabis help cachexia?
The controlled evidence does not support it. The largest randomised trial, in cancer-related anorexia-cachexia syndrome, found no significant difference between a cannabis extract, THC alone and placebo, and was stopped early.
Is cachexia the same as loss of appetite?
No. Cachexia is a wasting syndrome driven by an underlying illness and involves loss of skeletal muscle that eating more does not reverse. Appetite loss can accompany it, and can also occur on its own from nausea, pain or treatment side effects.
What about cannabis for chemotherapy sickness?
That is a different indication with a stronger evidence base, and one licensed cannabis-based medicine is recommended for chemotherapy-induced nausea and vomiting where standard anti-sickness medicines have not worked.
Can it be prescribed for weight loss in general?
Weight loss without a diagnosis is not an indication. A specialist would want to know what is causing it, and unexplained weight loss needs investigating rather than treating symptomatically.
How does the endocannabinoid system relate to appetite?
The body has an endocannabinoid system involved in appetite and metabolism, which is why increasing appetite is the effect cannabis is best known for. In cachexia, though, the muscle loss is driven by inflammatory and metabolic processes that eating more does not reverse, so stimulating appetite does not treat the syndrome.
If a specialist does consider it, how is treatment managed?
Any cannabis-based medicine is started at a low dose and titrated slowly under supervision, usually as oils or capsules by mouth, and reviewed at follow-up. Because people with cachexia are often frail and on several medicines, side effects and interactions are watched closely, and treatment that is not helping is stopped.
Should my palliative care team and GP be involved?
Yes. Specialist dietetic and palliative care input addresses the treatable symptoms around cachexia, and keeping your GP and treating team informed keeps your care joined up and your record complete. This is not something to arrange in isolation from the team managing your illness.
Sources and further reading
Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.
- Strasser F, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome. Journal of Clinical Oncology (2006)
- NICE guideline NG144: Cannabis-based medicinal products
- NHS: Cancer
- NHS: Medical cannabis (and cannabis oils)
- MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use